Every 10-Q that OnKure Therapeutics (OKUR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OKUR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OKUR filings page.
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision small-molecule drugs targeting mutant PI3Kα for vascular anomalies and cancers. For the six months ended June 30, 2026, it reported a net loss of $30.5 million, compared with $31.3 million in the prior-year period.
Research and development expenses were $24.3 million and general and administrative expenses were $8.2 million. Cash, cash equivalents and marketable securities totaled $176.4 million, strengthened by a $150.0 million March 2026 private placement of common stock and pre-funded warrants. Management believes this liquidity funds its current operating plan for at least the next 12 months as it prepares IND submissions for OKI-345 and OKI-355 in the first half of 2027.
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision small-molecule drugs targeting mutant PI3Kα for cancers and vascular anomalies. It reported a net loss of $15.2 million for the quarter ended March 31, 2026, slightly improved from $15.9 million a year earlier, as research and development expenses decreased to $11.7 million and general and administrative costs held roughly flat at $3.9 million.
A key event was a private placement completed on March 31, 2026, providing approximately $150.0 million in gross proceeds through the sale of 26,713,638 Class A shares at $4.15 per share and 9,430,957 pre-funded warrants at $4.1499 per underlying share. After this financing, cash and cash equivalents rose to $192.1 million from $59.1 million at year-end 2025, and management now believes available cash will fund the current operating plan for at least 12 months.
As of May 4, 2026, there were 40,395,480 Class A shares outstanding, reflecting significant dilution from equity issuances. OnKure is prioritizing next-generation PI3Kα pan-mutant programs OKI-345 and OKI-355, while not planning further independent clinical development of OKI-219. The company continues to operate at a loss and anticipates increased spending as its pipeline progresses.
OnKure Therapeutics (OKUR) reported a wider quarterly loss as it advanced its lead oncology program. For Q3 2025, net loss was $14.7 million versus $11.6 million a year ago, driven by higher operating expenses. Research and development expense rose to $11.9 million and general and administrative expense to $3.6 million, reflecting increased personnel and share-based compensation. Interest income was $0.8 million.
Balance sheet capacity narrowed but remains solid for near-term plans. Cash and cash equivalents were $70.3 million at September 30, 2025, down from $110.8 million at year-end, with total assets of $72.8 million and stockholders’ equity of $66.4 million. Management believes existing cash will fund the current operating plan for at least 12 months from the financial statement issuance date.
Corporate update: The company completed its reverse recapitalization with Reneo on October 4, 2024 and a concurrent $65.0 million financing. As of November 5, 2025, shares outstanding were 12,861,672 Class A and 686,527 Class B.